Objective: Endovascular treatment is increasingly used to treat complicated aortic pathology. The aim of the study was to assess if compared with operative repair, thoracic endovascular repair of aorta (TEVAR) was associated with a cost benefit in management of diseases affecting the descending thoracic aorta. We also compared early and mid-term outcomes between the two groups. Methods: Clinical characteristics, outcomes and hospitalisation costs of 84 consecutive patients undergoing intervention for conditions affecting the descending thoracic aorta were reviewed retrospectively. Hospitalisation costs were calculated from National Health Service (NHS) reference costs for staff time, consumables, transfusion and length of stay. Results: Apart from a higher frequency of acute type B dissection (16/45 vs 5/39, p = 0.047) in the TEVAR group, the baseline characteristics were similar. TEVAR was associated with significant reductions in morbidity (renal dysfunction 11 (31%) vs 5 (10%) p = 0.025; inhospital death 7 (20%) vs 3 (6%), p = 0.03; median intensive therapy unit (ITU) stay 6 (3-11) vs 1 (1-4), p < 0.0001). TEVAR was associated with significantly increased procedural costs (£2468 (s2961) vs £9581 (s11495) p 0.0001). This was chiefly attributable to the cost of endovascular stents. There was no significant difference in overall hospitalisation costs. TEVAR was associated with significantly lower freedom from death or re-operation (log rank p = 0.048). Conclusions: TEVAR is associated with reduced morbidity and mortality in the short term. However, no cost benefit was seen with TEVAR even in the short term. In the long term, due to increased risk of re-interventions TEVAR may actually prove to be a more expensive therapeutic option. #
Introduction
Management of descending thoracic aortic pathologies is a challenging prospect. Historically, the therapeutic options for treatment of descending thoracic aortic pathology ranged from a very conservative medical management to an extremely invasive open surgical repair in situations such as impending rupture and organ mal-perfusion due to aortic branch vessel compromise. Following reports of successful stent grafting of the thoracic aorta by Dake [1] and Nienaber [2] , thoracic endovascular repair of aorta (TEVAR) has emerged as another option for management of thoracic aortic pathologies.
In the last decade, there has been a dramatic rise in the incidence of TEVAR as a therapeutic option for management of descending thoracic aortic pathologies. Open surgical repair, despite advances in techniques towards spinal cord protection, organ preservation and refinements of prosthetic grafts, is associated with a mortality ranging from 5% to 10% and significant postoperative morbidity including paraplegia, pulmonary dysfunction and renal failure [3] . TEVAR, on the other hand, by allowing less invasive exclusion of thoracic aortic pathology from the systemic circulation is perceived to be better tolerated than open surgical repair [4] . TEVAR has also been reported to significantly reduce peri-operative mortality [5, 6] . Statistically significant reduced incidences of spinal cord ischaemia, respiratory failure and renal insufficiency have all been reported in the TEVAR group [6] .
Compared with patients treated with open surgical repair, TEVAR is also associated with significantly shorter length of stay in the intensive care unit (ICU), as well as significantly reduced overall hospital stay [5] and require fewer blood transfusions [7] . A shorter hospital and ICU stay coupled with lesser utilisation of other resources inherent with open surgical repair such as transfusion of blood products may intuitively be translated into reduced hospitalisation costs, thereby reducing the financial burden on the institution and the health-care system.
The aim of this study was therefore to examine the hypothesis that compared with operative repair TEVAR may be a less expensive option for management of descending thoracic aortic pathologies. In order to compare their effectiveness at treating the descending thoracic aortic pathologies, we also compared the early and mid-term outcomes of the two intervention modalities.
Material and methods

Patient selection
A consecutive series of patients undergoing intervention on the descending aorta AE arch, either open surgical repair or TEVAR, over a period of 13 years (between April 1996 and April 2009), were identified in a single institution. Following the introduction of TEVAR in our practice, where intervention was indicated, TEVAR was used preferentially in the acute setting, for instance, acute type B aortic dissections and traumatic transections. Surgery was used in chronic dissections and where a more extensive repair was required concomitant abdominal aortic or arch surgery was contemplated. We carried out TEVAR in marfan patients in the early period but currently treat them surgically.
Data collection
Demographics, pre-, peri-and postoperative data were collected prospectively on all patients undergoing cardiac surgery and entered into a database (Patient Analysis and Tracking System (PATS). Deaths occurring post-hospital discharge were identified from mortality data provided by National Health Service (NHS) Strategic Tracing Service (NSTS). All patients were successfully matched to the NSTS database.
Hospital costs were calculated from NHS reference costs for staff time, consumables, transfusion and length of stay. Definitions with respect to the operative priority, pre-morbid conditions and postoperative complications are those used in the National Adult Cardiac Database and accepted by the Society of Cardio-thoracic Surgeons of Great Britain and Ireland available at www.scts.org.
Statistical analysis
Baseline and operative characteristics were compared using the chi-squared or Fisher's exact test (categorical variables) or the Mann-Whitney U test (continuous variables).
As the number of adverse outcomes was few, the results were compared 'without' adjustment for baseline and operative characteristics. Binary variables were compared using Fisher's exact test, and continuous variables were compared using the Mann-Whitney U test (ICU stay). Kaplan-Meier estimates were used to compare re-intervention and survival.
All analyses were carried out using Stata W (Stata Corporation, College Station, TX, USA).
Operative techniques
Over the period, a range of surgical techniques was practiced; nevertheless, there was broad consensus with respect to the operative strategy, perfusion techniques, neuroprotective and blood conservation strategies.
Surgical techniques
All the operations were performed through a left thoracotomy incision. Depending on the pathology, either deep hypothermic circulatory arrest (DHCA) or left heart bypass technique was used. Where DHCA was required, the patients were cooled down to 18 8C prior to initiation of the circulatory arrest. The left ventricle was vented via a small left anterior thoracotomy in selected cases. Re-implantation of intercostal arteries was also undertaken selectively depending on the surgeon's preference.
Perfusion techniques
Cardiopulmonary bypass was established through cannulation of the common femoral artery and venous drainage provided by cannulation of the femoral vein with or without cannulation of the left atrial appendage. Cerebral protection was achieved by profound hypothermia. Latterly, insertion of cerebrospinal fluid (CSF) drainage catheter has been routine in all surgical interventions on the descending aorta.
Anaesthetic techniques
Fentanyl 20-35 mg kg À1 and pancuronium 0.15 mg kg
À1
were used in all cases along with isoflurane and/or propofol pre-bypass. Propofol 3-5 mg kg À1 h À1 infusion was used during the bypass routinely. Where DHCA was required, a thiopentone bolus 20-30 mg kg À1 was administered. Additionally, dexamethasone up to 8 mg was administered prior to circulatory arrest. Latterly, trans-oesophageal echocardiography was used routinely intra-operatively. Use of ice packs for cerebral protection during DHCA depended on individual preference.
TEVAR
Selection of the stent graft was based on careful assessment of the pathology by reconstruction and analysis of the diagnostic images. The Valiant (Medtronic, Minneapolis, MN, USA) stent graft, which represents the latest evolution of the talent stent graft, was used most commonly in the study group. On occasions, the RELIANT W Stent Graft Balloon Catheter was used instead. The device was inserted via the femoral artery. A surgical exposure of the femoral artery was performed and a Dacron graft conduit stitched to the arteriotomy to minimise trauma to the femoral artery.
Results
A consecutive series of 84 patients undergoing intervention on the descending thoracic aorta were included in the study. In the early part of the study between 1996 and 2001, operative repair was the exclusive intervention on the descending thoracic aorta. TEVAR was introduced in our institution in 2002, and has currently become the predominant form of intervention on the descending aorta (Fig. 1) . Surgical repair was carried out in 21 patients after 2002, while TEVAR was carried out in 45 cases during the same time.
Baseline characteristics were broadly similar across the two groups (Table 1) . However, compared with operative repair, TEVAR was used in a higher proportion of patients presenting with emergent pathology on the descending aorta, 12 (33%) versus 21 (43%), p value 0.47. Apart from a higher frequency of acute type B dissection (16/45 vs 5/39, p = 0.047) in the TEVAR group, the baseline characteristics were similar. Broadly, the nature of pathology on the descending aorta did not determine the intervention; and both operative repair and TEVAR were used in an equal proportion of aneurysms, traumatic transactions and dissections (Table 2) . However, subgroup analysis of the dissection group revealed that acute dissections were managed in a significantly higher proportion of cases by TEVAR, whereas chronic dissections were managed mainly by operative repair.
While staff costs, costs of consumables, transfusion, intensive care and hospital stay were all significantly higher in patients undergoing operative repair, this was offset by the high costs of stents leading to significantly higher procedural costs in the TEVAR group (Table 3) . As a result, in our study we did not see any differences in the overall hospital costs for an index hospital admission.
Early postoperative morbidity was, in general, higher in the operative repair group, which was also associated with a significantly higher early in-hospital mortality (Table 4) .
However, even with a comparatively shorter period of followup in the TEVAR group, risk of re-intervention remained higher along with the risk of late death (Table 5 , Figs. 1  and 2 ). Log-rank test showed a similar survival (Fig. 1 ) but a greater freedom from re-intervention in the surgical repair group as compared with the TEVAR group (Fig. 2) at 4 years.
Discussion
In our study, compared with operative repair, TEVAR was associated with a better short-term outcome but similar midterm outcome. Incidence of re-interventions was higher in the TEVAR group and it did not prove to be a more costeffective option for management of descending thoracic aortic pathologies.
The early mortality for aneurysmal disease of the descending aorta treated with TEVAR has been reported between 2% and 19% [8, 9] with a much higher mortality (25%) for complicated acute type B dissections [10] . The mortality following open surgical repair from higher volume centres has been reported between 3% and 8% [11, 12] ; however, metaanalysis of reported single and multicentre studies shows an average mortality to be about 14% [7] . While there has been general agreement that TEVAR is associated with better early outcome, there have been contradictory reports suggesting [ ( ) T D $ F I G ] significantly better outcome with surgical repair [13] even in the early period. However, contemporary data published from other centres report no difference in the early mortality between the operative and TEVAR groups [14, 4] .
Despite excellent operative results from few centres, there is still general acceptance that in the early postoperative period TEVAR has a survival advantage over operative repair. However, it is increasingly becoming evident that this benefit seems to be lost over a period of time. This indeed has been the finding in our study. Other studies on the subject have similarly concluded that the lower initial mortality advantage of TEVAR is lost over a period of time [14] and sustained benefits on survival remain unproven [7] . With regard to major postoperative complications such as stroke and paraplegia, operative repair is associated with a paraplegia risk of 2-4% [15] and a stroke rate reported in large series to be between 1.5% and 3.5% [16, 17] TEVAR, on the other hand, is associated with a reported paraplegia rate between 0% and 3.6% [18, 19] . The incidence of stroke was historically higher at about 7% [20] but with the modern stent-graft deployment system this is now reported to be lower and a recent meta-analysis reported an average of 4% [21] . In keeping with our results, a recent meta-analysis has shown TEVAR to be associated with a significant reduction in the risk of renal dysfunction, incidence of transfusion and re-operation for bleeding. A significant reduction in overall hospital and intensive care stay was also reported [7] .
Interestingly, despite the minimal trauma involved with TEVAR, studies carried out to assess and compare outcome and quality of life after surgical and endovascular intervention have failed to demonstrate any benefit of TEVAR over operative repair in terms of overall quality of life, or anxiety and depression scores [4] .
TEVAR was not found to be cost-effective in our study for the index intervention in the early period. In the early period, the reduction in costs due to reduced transfusion requirements, shorter hospital stay and reduction in postoperative complications were offset by the high costs of the stents. Both the number of stents deployed and the type influence the overall cost, with fenestrated and branched grafts costing more. The long-term cost implications of TEVAR are significant and are largely influenced by the risk of re-interventions and costs of follow-up. Meta-analysis of endovascular stent-graft placement in aortic dissection data suggested a re-intervention rate of nearly 12% over a mean follow-up period of approximately 2 years [22] .
As results and durability data of stent grafts beyond 10 years are largely unknown, patients undergoing TEVAR will need monitoring for long periods of time with computed tomography scan or magnetic resonance imaging. Thus, a higher risk of re-interventions in the early and mid-term due to endoleaks, stent migration, stent fracture, stent-graft thrombosis and longer-term surveillance issue for possible stent-graft deterioration will prove TEVAR to be a much more expensive option compared with operative repair.
Data available from interventions on abdominal aorta reveal a similar picture. During an 8-year follow-up period, endovascular repair was found to be associated with a greater risk of graft-related complications and higher risk of re-intervention and was found to cost more than the operative repair group [23] . Another study evaluating the clinical effectiveness and cost effectiveness of endovascular aneurysm repair (EVAR) of infra-renal abdominal aortic aneurysms in patients at varying levels of risk concluded that open repair is more likely to be cost-effective than EVAR on average in patients considered fit for open surgery [24] .
Limitations
There are few important limitations with our study. The first and the foremost being that the patients for surgery and TEVAR seem to be from two different eras and hence the costs involved would be influenced by inflation. Also, the case mix is heterogeneous and the extent of intervention variable between the two groups, complicating the comparison in costs and outcomes. The limitations inherent to a retrospective study are seen in our study too; while the study succeeds in addressing the cost implications on a broad level, a randomised controlled trial with defined operative indications would allow for a more subtle comparison.
Conclusions
TEVAR did not prove to be cost-effective compared with operative repair of descending thoracic aortic pathologies in the short term. Any survival advantage in the early period is lost at follow-up. Taking into account the increased risk of reinterventions, TEVAR may actually prove to be more expensive compared with operative repair.
